Recent 8-K filings for AIDX
Highest-materiality recent filing
20/20 Biolabs cuts warrant exercise price to $2.25, from $11.42/$8.00
- On April 23, 2026, amended Streeterville warrants lowering exercise price to $2.25/share.
- Warrants cover 3,627,627 shares; prior prices were $11.42 and $8.00.
-
Six directors elected: Jonathan Cohen, John G. Compton, Richard M. Cohen, Prasanth Reddy, John W. Rollins, Michael A. Ross; each received >2.6M votes for.
-
20/20 BioLabs Q2 revenue up 37% to $0.7M; OneTest revenue up 47%
Q2 2026 total revenue $0.7M, up 36.5% YoY; OneTest revenue $0.7M, up 47.1%, 95.3% of total.
-
Company furnished investor presentation for August 5, 2026 webinar under Regulation FD.
-
20/20 Biolabs enters standstill with Streeterville; receives Nasdaq bid price deficiency notice
Standstill agreement with Streeterville: 120-day forbearance on conversion of Series E preferred unless stock price >10% above Nasdaq Minimum Price.
-
Presentation furnished as Exhibit 99.1 for Regulation FD purposes.
-
20/20 Biolabs reduces stockholder meeting quorum from majority to one-third
Board adopted Amendment No. 1 to Bylaws on May 19, 2026.
-
20/20 BioLabs Q1 revenue $0.4M, net loss $2.2M; expects Q2 rebound from firefighter programs
Q1 revenue $0.4M vs $0.6M YoY; net loss $2.2M vs $0.8M; gross margin 17.8% vs 29.9%.
-
20/20 Biolabs cuts warrant exercise price to $2.25, from $11.42/$8.00
On April 23, 2026, amended Streeterville warrants lowering exercise price to $2.25/share.
-
20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement
Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material